San Diego-based Excaliard Pharmaceuticals, a developer of biopharmaceuticals for treating skin scarring, has been acquired by Pfizer. Financial terms of the buy were not disclosed. Excaliard was venture backed by RiverVest, Alta Partners, ProQuest Investments, and Isis Pharmaceuticals. Excaliard's technology is based on technology licensed from Isis Pharmaceuticals. Excaliard's lead product is an antisense oligonucleotide, which isi being used for treatment of skin fibrosis, preventing disfiguring skin scarring following surgery or traumatic injury.